Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value
| Autor: | Sonia Eiras, José María García-Acuña, José Ramón González-Juanatey, Alfonso Varela-Román, Marinela Couselo-Seijas, Ezequiel Álvarez, Mercedes González-Peteiro, Rosa M. Agra, Cristina Almengló |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Acute coronary syndrome Adrenergic beta-Antagonists Kaplan-Meier Estimate ADAM17 Protein Peptidyl-Dipeptidase A Losartan Angiotensin Receptor Antagonists Enalapril Internal medicine Drug Discovery medicine Human Umbilical Vein Endothelial Cells Humans Myocardial infarction Acute Coronary Syndrome Long-term cardiovascular prognosis Genetics (clinical) Metoprolol Aged Aged 80 and over Heart Failure biology business.industry Angiotensin II Soluble angiotensin-converting enzyme-2 Angiotensin-converting enzyme Middle Aged medicine.disease Prognosis Chronic heart failure Pharmacotherapy Heart failure Cohort biology.protein Cardiology Molecular Medicine Original Article Female Angiotensin-Converting Enzyme 2 business medicine.drug |
| Zdroj: | Journal of Molecular Medicine (Berlin, Germany) |
| ISSN: | 1432-1440 0946-2716 |
| Popis: | The main objective was to compare the meaning of soluble angiotensin-converting enzyme-2 (sACE2) plasma levels modulation on the prognosis of two cohorts of heart failure (HF) and acute coronary syndrome (ACS). We conducted an observational clinical study where sACE2 was measured in two cohorts of HF or ACS (102 patients each), matched by age and gender. The primary endpoint (cardiac death) and the secondary endpoints (non-fatal myocardial infarction or HF readmission) were registered during a 5-year follow-up period. Association with pharmacotherapy was studied, and the effects of cardiovascular drugs on ACE isoforms expression were analysed in human umbilical vein endothelial cells (HUVEC) in vitro. The levels of sACE2 were significantly higher in the HF than ACS cohort. sACE2 was inversely related with the leukocytes number and directly with urea levels. In the ACS cohort, sACE2 was associated with age and glycaemic parameters, but in the HF cohort, the association was with N-terminal pro-B-type natriuretic peptide. The levels of sACE2 were related to long-term prognosis and confirmed as a non-independent predictor in the HF cohort. Soluble ACE2 was higher in patients treated with angiotensin receptors blockers and β-blockers, accordingly with losartan and metoprolol upregulation of ACE1 and ACE2 in HUVECs. Plasma levels of sACE2 were higher in HF than in ACS, independently of age and gender, and were related to long-term cardiac death in the HF cohort. Losartan and metoprolol, but not enalapril, upregulated ACE expression in endothelial cells, accordingly with higher levels of sACE2 in patients using these drugs. Supplementary Information The online version contains supplementary material available at 10.1007/s00109-021-02129-4. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink